LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Transcription Factor Deficit Spurs Tumor Development

By LabMedica International staff writers
Posted on 28 Jun 2017
Print article
Image: A photomicrograph of human breast cancer line MCF-7 cells (Photo courtesy of Wikimedia Commons).
Image: A photomicrograph of human breast cancer line MCF-7 cells (Photo courtesy of Wikimedia Commons).
A team of British cancer researchers found that the transcription factor proline-rich homeodomain protein (PRH/HHEX) played a tumor suppressive role in the breast, and they provided an explanation for the finding that low PRH mRNA levels were associated with a poor prognosis in breast cancer.

Breast tumors progress from hyperplasia to ductal carcinoma in situ (DCIS) and invasive breast carcinoma (IBC). In order to study the role of the PRH/HEX transcription factor in this progression, investigators at the University of Birmingham (United Kingdom) adapted a population of human breast cancer MCF-7 cells to under or over produce PRH/HEX.

They reported in the June 12, 2017, online edition of the journal Oncogenesis that transcriptionally inactive phosphorylated PRH was elevated in DCIS and IBC compared with tissues in the normal breast. To determine the consequences of PRH loss of function in breast cancer cells, they induced PRH depletion in their line of MCF-7 cells. They showed that PRH depletion resulted in increased MCF-7 cell proliferation in part at least due to increased vascular endothelial growth factor signaling. Moreover, they demonstrated that PRH depletion increased the formation of breast cancer cells with cancer stem cell-like properties.

In a mouse model, PRH overexpression inhibited the growth of mammary tumors. Taken together, these data indicated that PRH played a tumor suppressive role in the breast, and they provided an explanation for the finding that low PRH mRNA levels were associated with a poor prognosis in breast cancer.

Senior author Dr. Padma Sheela Jayaraman, senior lecturer in cancer biology at the University of Birmingham, said, "PRH is a protein that controls and regulates when genes are switched on or off. However, prior to our research, the role of this protein in breast cancer has been poorly understood. In the laboratory, we found that when PRH protein levels are reduced in a breast tumor the cells are more able to divide, speeding up the progression of the tumor. Moreover, we identified some of the genes which are regulated by PRH and specifically contribute to the increased cell division."

"We made the significant finding that high levels of PRH actually blocked the formation of the tumors, therefore our data suggests that PRH can block tumor formation in some breast cancers," said Dr. Jayaraman. "We propose that monitoring PRH protein levels or activity in patients with breast cancer could be particularly important for assessing their prognosis. In addition, since PRH is known to be important in multiple cell types, this work has important implications for other types of cancer."

Related Links:
University of Birmingham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crytal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more